Company intelligence / Profile preview

TRACT Therapeutics

Chicago, Illinois, United Statestracttherapeutics.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Phase 1 clinical trial in kidney transplant demonstrated no safety concerns, and two-year patient biopsies were normal with no rejection. The company is now preparing for a multi-center Phase 2 clinical trial investigating the reduction of immunosuppressant drugs in living donor kidney transplant recipients.

Therapeutic areas: Immunology
Modalities: Regulatory T cell therapy
Industry: Biotech

Drug pipeline

1 asset

TregCel

Phase 2

Indications: Organ transplant rejection, Autoimmune diseases

Partnerships

Taiwan Bio Therapeutics

Beyond the preview

Go deeper on TRACT Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRACT Therapeutics.

Explore the full profile